ANN ARBOR, Mich., Oct. 24 /PRNewswire/ -- QuatRx Pharmaceuticals, a privately-held biopharmaceutical company focused on research and development of therapeutic compounds for the treatment of major endocrine, metabolic and cardiovascular diseases, today announced that Anders P. Wiklund has been appointed to the Company's board of directors.
Mr. Wiklund brings over 30 years of global pharmaceutical and biotechnology experience in sales, operations, mergers & acquisitions and strategic business development to the QuatRx board of directors. He is currently principal of Wiklund International Inc., a biotechnology advisory firm, and serves on the boards of several other biopharmaceutical companies. Mr. Wiklund was also on the board and was a cofounder of Esperion Therapeutics. Previously, Mr. Wiklund led corporate business development at Pharmacia, Inc. (later Pharmacia & Upjohn). Prior to that, Mr. Wiklund was chief executive officer and president of KabiVitrum, Inc. and Kabi Pharmacia, Inc., as well as president of KabiVitrum International in Stockholm, Sweden. Mr. Wiklund received his Master's of Pharmacy from the Pharmaceutical Institute in Stockholm, Sweden and studied business administration at the University of Stockholm.
Mr. Wiklund's appointment is part of QuatRx's merger with Hormos Medical in May in which the companies agreed to add one representative of the Hormos investor group to QuatRx's board of directors. His election expands QuatRx's board to nine members, including eight non-employee directors.
"Anders Wiklund's broad knowledge of the biopharmaceutical industry and his international business background make him an ideal addition to the QuatRx board of directors," said Robert Zerbe, M.D., president and chief executive officer of QuatRx. "He brings extensive knowledge and in-depth experience that is directly related to our core therapeutic focus and we look forward to working with him in the years ahead."
QuatRx Completes Second Tranche of Series D Financing
QuatRx also announced that it has completed the second tranche of the Company's previously announced $31 million Series D Financing. The Company originally announced the initial closing of this third round of private equity financing in December 2004. Thomas Weisel Healthcare Ventures was lead investor in the financing. QuatRx has raised nearly $72 million in private equity financing since its incorporation in December 2000.
About QuatRx
QuatRx Pharmaceuticals Company, a biopharmaceutical company, focuses on research and development of therapeutic compounds primarily for the treatment of major endocrine, metabolic and cardiovascular diseases, especially endocrine diseases of aging and dyslipidemia. QuatRx has its headquarters in Ann Arbor, Michigan, with a significant presence in Europe through Hormos Medical Corp. (a wholly-owned subsidiary of QuatRx Pharmaceuticals Company), located in Turku, Finland. QuatRx's robust pipeline includes four compounds in clinical development. The research activities of the company are based on its expertise in tissue-specific steroid hormone effects at the molecular and cellular level. With significant financial backing from top-tier venture capital firms and strong development capabilities, QuatRx continues to advance and expand its portfolio of development-stage compounds.
QuatRx Pharmaceuticals CompanyCONTACT: Company Contact: Julia Owens of QuatRx Pharmaceuticals Company,+1-734-913-9900 x121; or Media Contact: Lisa Koen of Berry & Company,+1-212-253-8881
Web site: http://www.quatrx.com/
